EGFR and non-small cell lung carcinoma: Furthermore, NSCLC cells with acquired resistance to gefitinib or osimertinib (AZD9291) showed EMT characteristics, with a decrease in E-cadherin, and increases in vimentin and stemness, without any EGFR secondary mutations (12).